News | April 04, 2022
USFDA grants priority review to Roche’s Actemra/RoActemra to treat Covid-19
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
An estimated 21 million American women experience BV
No new studies have been requested
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Subscribe To Our Newsletter & Stay Updated
